The roles of epigenetic modifications of proapoptotic BID and BIM genes in imatinib-resistant chronic myeloid leukemia cells

References

• Zheng C, Haak M, Brors B, Frank O, Giehl M, Fabarious A: Gene expression profiling of CD33+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis. Leukemia 2006;20:1028–34.
   PubMed Web of Science ®Google Scholar
• Cillioni D, Saglio G. CML: a model for targeted therapy. Best Pract Res Clin Haematol. 2009;22:285–94.
   PubMed Web of Science ®Google Scholar
• Radich JP. The biology of CML blast crisis. Hematol Am Soc Hematol Educ Program Book, vol 1, 2007;384–91.
   Google Scholar
• Bixy D, Talpaz M. Mechanism of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia recent therapeutic strategies to overcome resistance. Hematol Am Soc Hematol Educ Program Book, vol 1, 2009;461–7.
   Google Scholar
• Barnes DJ, Melo JV. Primitive, quiescent and difficult to kill: the role of non-proliferating stem cells in chronic myeloid leukemia. Cell Cycle. 2006;5:2862–6.
   PubMed Web of Science ®Google Scholar
• Baran Y, Ural AU, Gunduz U. Mechanisms of cellular resistance to imatinib in human chronic myeloid leukemia cells. Hematology 2007;12(6):497–503.
   PubMed Web of Science ®Google Scholar
• Baran Y, Salas A, Senkal CE, Gunduz U, Bielawski J, Obeid LM, et al. Alterations of ceramide/sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells. J Biol Chem. 2007;282(15):10922–34.
   PubMed Web of Science ®Google Scholar
• Smith LT, Otterson GA, Plass C. Unraveling the epigenetic code of cancer for therapy. Trends Genet. 2007;23:449–56.
   PubMed Web of Science ®Google Scholar
• Fandy TE, Carraway H, Gore SD. DNA demethylating agents and histone deacetylase inhibitors in hematologic malignancies. Cancer J. 2007;13:40–4.
   PubMed Web of Science ®Google Scholar
• Patra SK, Szyf M. DNA methylation-mediated nucleosome dynamics and oncogenic Ras signalling insights from FAS, FAS ligand and RASSF1A. FEBS J. 2008;275:5217–35.
   PubMed Web of Science ®Google Scholar
• Martinez AM, Cavalli G. The role of polycomb group proteins in cell cycle regulation. Cell Cycle 2006;5:1189–97.
   PubMed Web of Science ®Google Scholar
• Negishi M, Saraya A, Miyagi S, Nagao K, Inagaki Y, Nishikawa M: BMI1 cooperates with Dnmt1-associated protein 1 in gene silencing. Biochem Biophys Res Commun. 2007;353:992–8.
   PubMed Web of Science ®Google Scholar
• Kanno R, Janakıraman H, Kanno M. Epigenetic regulator polycomb group protein complexes control cell fate and cancer. Cancer Sci. 2008;99:1077–84.
   PubMed Web of Science ®Google Scholar
• Simon JA, Lange CA. Roles of the EZH3 Histone methyltransferase in cancer epigenetics. Mutat Res. 2008;647:21–9.
   PubMed Web of Science ®Google Scholar
• Martin C, Zhang Y. The diverse functions of histon lysine methylation. Nat Rev. 2005;6:838–47.
   Google Scholar
• Besy JD, Carey N. Epigenetic covalent modifications of DNA and chromatin proteins strongly effect gene expression and cellular activity, and epigenetic misregulation occurs in several diseases, especially cancer. Drug Discov Today 2010;15:65–70.
   PubMedGoogle Scholar
• Pfaff MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29:45.
   Web of Science ®Google Scholar
• Ding L, Kleer CG. Enhancer of Zeste 2 as a marker of preneoplastic progression in the breast. Cancer Res. 2006;66:9352–93.
   PubMed Web of Science ®Google Scholar
• Kuzmichev A, Margueron R, Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation. Proc Natl Acad Sci USA 2005;102:1859–64.
   PubMed Web of Science ®Google Scholar
• Garcia EM, Licht JD. Deregulatin of H3K27 methylation in cancer. Nat Genet. 2010;42:100–1.
   PubMed Web of Science ®Google Scholar
• McHugh BJ, Fullen DR, Kleer CG. Expression of polycomb group protein EZH2 in nevi and melanoma. J Cutan Pathol. 2007;34:597–600.
   PubMed Web of Science ®Google Scholar
• Wagener N, Holland D, Bulkescher J, Mertens IC, Seyler KH, Zentgraf H. The enhancer of zeste homolog 2 gene contributes to cell proliferation and apoptosis resistance in renal cell carcinoma cells. Int J Cancer 2008;123:1545–50.
   PubMed Web of Science ®Google Scholar
• Hinz S, Kempkensteffen C, Christoph F, Krause H, Schrader M, Schostak M. Expression parameters of the polycomb group protein BMI1, SUZ12, RING1 and CBX7 in urothelia carcinoma of the bladder and their prognostic revelance. Tumour Biol. 2008;29:323–9.
   PubMed Web of Science ®Google Scholar
• Ougolkov AV, Bılım VN, Billadeau DD. Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase EZH2. Clin Cancer Res. 2008;14:6790–6.
   PubMed Web of Science ®Google Scholar
• Pizzati L, Binato R, Cofre J, Gomes BE, Dobbin J, Hausmann ME. SUZ12’ is a canditate target of the non-canonical WNT pathway in the progression of chronic myeloid leukemia. Genes Chromosomes Cancer 2010;49:107–18.
   PubMed Web of Science ®Google Scholar
• Brooks CL, Gu W. How does SIRT1 affect metabolism, senesence and cancer? Nat Rev Cancer 2009;9:123–8.
   PubMed Web of Science ®Google Scholar
• Luı T, Iiu PY, Marshall M. The critical role of the class III histone deacetylase SIRT1 in cancer. Cancer Res. 2009;69:1702–5.
   PubMed Web of Science ®Google Scholar
• Kwon HS, Ott M. The ups and downs of SIRT1. Trends Biochem Sci. 2008;33:517–25.
   PubMed Web of Science ®Google Scholar
• Kurado J, Puthalakt H, Cragg MS, Kelly PN, Boullet P, Huang D. Bim and Bad mediate imatinib-induced killing of BcrIAbl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci USA 2006;103:14907–12.
   PubMed Web of Science ®Google Scholar
• McGarvey KM, Greene E, Fahrener JA, Jenuwein T, Baylin SB. DNA Methylation and complete transcriptional silencing of cancer genes persist after depletion of EZH2. Cancer Res. 2007;67:5097–102.
   PubMed Web of Science ®Google Scholar
• Widschwendter M, Fiegl H, Egle D, Müeller-Holzner E, Spizzo G, Marth C. Epigenetic stem cell signature in cancer. Nat Genet. 2007;39:157–8.
   PubMed Web of Science ®Google Scholar
• Jose-Eneriz E, Agirre X, Jimenez-Velasco A, Cordeu L, Martin U, Arqueros U. Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukemia. Eur J Cancer 2009;45:1877–89.
   PubMed Web of Science ®Google Scholar
• Schlesnger Y, Straussman R, Keshet I, Farkash S, Hecht M, Zimmerman J. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet. 2007;39:232–6.
   PubMed Web of Science ®Google Scholar
• McCabe MT, Lee EK, Vertino PM. A Multifactorial signature of DNA sequence and polycomb binding predicts aberrant CpG island methylation. Cancer Res. 2009;69:282–90.
   PubMed Web of Science ®Google Scholar
• Fiskus F, Wang Y, Sreekumar A, Buickley KM, Shi H, Jillella A. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood 2009;114:2733–43.
   PubMed Web of Science ®Google Scholar
• Kondo Y. Epigenetic cross-talk between DNA methylation and histone modification in human cancers. Yonsei Med J. 2009;50:455–63.
   PubMed Web of Science ®Google Scholar